2. Academic Validation
  3. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones

Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones

  • J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h.
Steven L Colletti 1,  Jessica L Frie,  Elizabeth C Dixon,  Suresh B Singh,  Bernard K Choi,  Giovanna Scapin,  Catherine E Fitzgerald,  Sanjeev Kumar,  Elizabeth A Nichols,  Stephen J O'Keefe,  Edward A O'Neill,  Gene Porter,  Koppara Samuel,  Dennis M Schmatz,  Cheryl D Schwartz,  Wesley L Shoop,  Chris M Thompson,  James E Thompson,  Ruixiu Wang,  Andrea Woods,  Dennis M Zaller,  James B Doherty
Affiliations

Affiliation

  • 1 Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. steve_colletti@merck.com
PMID: 12540232 DOI: 10.1021/jm025585h
Abstract

Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.

Figures